Result of General Meeting, Issue of Equity and Total Voting Rights
25 March 2014
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on transdermal technology, announces that, at its General Meeting held earlier today, all resolutions were duly passed.
Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. Admission is to take place in two tranches. It is expected that First Admission (consisting of 3,493,236 new Ordinary Shares) will be effective and trading will commence at 8.00 a.m. on 26 March 2014 and that Second Admission (consisting of 17,559,396 new Ordinary Shares) will be effective and trading will commence at 8.00 a.m. on 27 March 2014.
Immediately following Second Admission, the Company will have 98,982,208 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 98,982,208 and this figure may therefore be used by Shareholders from Second Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Terms in this announcement have the meaning given to them in the Circular issued in connection with the Placing and the announcement released on 7 March 2014 with the RNS Number 8494B.
James Barder, Futura's Chief Executive, commented: "We are very pleased to have completed this fundraising, and particularly with the level of support received both from our existing and new institutional shareholders."
For further information please contact:
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Buchanan Communications Limited
Mark Court / Sophie Cowles /
Tel: +44 (0) 20 7466 5000
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Commercial agreements are in place in relation to three products including agreements with international partners.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange (AIM: FUM).